AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04256278 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Spermotrend
Description: oral administration of antioxidants for three months
Study NCT04256278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spermotrend
Description: oral administration of antioxidants for three months
Study NCT05555719 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PowerScope Appliance
Description: PowerScope Appliance was installed on fixed orthodontic appliance
Study NCT00465972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxepin
Description: Doxepin 10 mg po nightly x duration of study length OR Temazepam 15 mg po nightly x duration of study length OR Placebo nightly x duration of study length
Study NCT00465972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temazepam
Description: Temazepam capsule 15 mg po nightly x duration of study
Study NCT00465972 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule nightly for duration of study
Study NCT01022151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxapram 1 mg/kg [group D]
Description: receive intravenous injection of 0.2 mL/kg of doxapram 5 mg/mL \[group D\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
Study NCT02394327 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 7-Fr Pigtail type naso-cholecystic drainage tube (Liguory nasal biliary drainage set; Wilson-Cook Medical, Salem, NC, USA)
Description: Endoscopic
Study NCT04215848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/Formoterol Fumarate 160 MCG-4.5 MCG Inhalation Powder
Description: After the patients who have all criteria, they will be randomized to take Budesonide/formoterol (160/4.5 μg/d) as need when they have symptoms.
Study NCT04215848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide 200Mcg Inhalation Powder
Description: After the patients who have all criteria, they will be randomized to take Budesonide (200 μg) twice daily
Study NCT04832126 — intervention group
Intervention type: GENETIC
Intervention: Genetic analysis
Description: Genomic DNA will be purified from peripheral blood or mouth swabs. Whole blood will be collected by peripheral phlebotomy in tubes containing K2EDTA as an anticoagulant. Blood samples will be stored at 4-8 oC for up to a week before DNA purification. Mouth swabs will be collected using the ORAcollect • DNA kit (OCR-100) (DNA Genotek Inc., Canada). Genomic DNA from whole blood or mouth swab samples will be purified using DNeasy Blood \& Tissue Kit (QIAGEN).
Study NCT00324649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Truvada once daily with continuation of the current NNRTI or PI at randomization.
Study NCT04393662 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of Muscle strength using a dynamometer
Description: Muscle strength will be measured in the elbow bilaterally using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA). Supination tests will be performed with the forearm in neutral position, 60° pronation and 60° supination. The elbow will be in 90° flexion, and the shoulder in 45° flexion. Constant pressure is applied to lever of device for 3 to 5 seconds. Maximum torque will be recorded automatically. For each position, three repetitions of 3s (to 5s) contractions will be performed with a break of 15 (or 30s) between the repetitions. There will be an additional break of 2 minutes between measurements of the supination strength in the different positions. This parameter will be analysed regarding asymmetry between both limbs.~Isometric endurance of forearm supination will be measured in neutral forearm. Flexion tests will be carried in the same setting as for supination. Flexion tests will be performed with the elbow in 90, 45 and 0° of flexion.
Study NCT04393662 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Range of motion clinical measurement (shoulder and elbow)
Description: The range of motion parameters (degree) of both shoulders and elbows will be documented. The circumference of the arm will be measured on the line between the medial acromion and the cubital fossa at 1/3 from the cubital fossa
Study NCT04393662 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Electromyography (EMG)
Description: Electromyographic (EMG) data will be collected using a wireless EMG system (myon AG, Schwarzenberg, Switzerland). Surface electrodes will be placed bilaterally on biceps and triceps following the guidelines of the SENIAM project (Surface ElectroMyoGraphy for the Non-Invasive Assessment of Muscles)
Study NCT04892719 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fluoroscopic chest imaging with 4Dx technology software analysis
Description: 4DxV utilizes a novel software algorithm to analyze data from cinefluoroscopy images to calculate regional ventilation and pulmonary function changes. Cinefluorography uses a fluorescent screen with X-rays to make real-time moving images the lung described below. This is the same x-ray fluoroscopy that is used in clinical imaging and the fluoroscopic imaging time is approximately 1 minute leading to an effective radiation dose of 2 mSv (200 mRem). This is significantly lower that the radiation exposure from a standard chest CT. Fluoroscopy images are acquired at each of five views for approximately enough time to capture at least one complete, continuous breath. The subject is required to remain in the same position for each of the five fluoroscopy imaging sequences. These images will be analyzed by the novel 4Dx technology to provide the 4Dx lung function analysis report.
Study NCT00808522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG
Description: recombinant hCG subcutaneous injections x 30 doses every other day lasting 60 days total.
Study NCT00808522 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: hCG
Description: recombinant hCG subcutaneous injections x 30 doses every other day lasting 60 days total.
Study NCT01465438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab 40 mg every other week
Study NCT02870985 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Stent
Study NCT02870985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coronary Stent
Study NCT01552837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seroquel
Description: for 4 weeks, 300 - 800 mg per day in 2 doses
Study NCT00436436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O6-benzylguanine
Study NCT00436436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Study NCT04093960 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus plantarum PS128
Description: 10 mg qd of escitalopram qd plus 300mg bid of Lactobacillus plantarum PS128 to enhance antidepressive effect
Study NCT04093960 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum PS128
Description: 10 mg qd of escitalopram qd plus 300mg bid of Lactobacillus plantarum PS128 to enhance antidepressive effect
Study NCT03215381 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: [11C]AZD1390
Description: \[11C\]AZD1390
Study NCT00837161 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips MR guided HIFU system
Description: HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis
Study NCT02398201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Description: Bezafibrate 200mg-600mg three times daily for 12 weeks.
Study NCT03455894 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DETECT'CHUTE CLINIBED
Description: The DETECT'CHUTE carpets will be positioned at night at the foot of the bed and set in motion by the nursing staff as soon as the elderly person goes to bed for the night. They will be withdrawn the next morning after the resident's rise. Each patient will benefit from the mat for 1 month.
Study NCT00790582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lithium carbonate
Description: The dosage of lithium carbonate will be adjusted for each individual. The maximum dose is 450mg/day.
Study NCT01198574 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron group
Description: Ferrous fumarate, 60 mg, weekly dose
Study NCT01198574 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A group
Description: Retinol, weekly dose, 15,000 IU
Study NCT01198574 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron and vitamin A group
Description: Ferrous fumarate, Retinol combination group, weekly dose
Study NCT01198574 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo group
Description: folic acid only as placebo group
Study NCT03538886 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Description: Revascularization of LAD lesion by CABG
Study NCT03538886 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Description: Revascularization of LAD lesion by PCI
Study NCT02494635 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Biomarker analysis
Study NCT02394327 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 7-Fr double pigtail plastic stent (Zimmon; Wilson-Cook Medical, Salem, NC, USA)
Study NCT01002404 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: angled and straight tipped guide wire
Description: Angled or straight tipped guide wire is used in the beginning of deep biliary cannulation in ERCP . If there is no success, other normal procedures (e.g. double wire cannulation and precut) are performed.
Study NCT00324649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine/lamivudine
Description: Continuation of the zidovudine + lamivudine containing regimen plus the current NNRTI or PI at randomization.
Study NCT04425538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Either infliximab or infliximab-abda will be used at the discretion of the investigator
Study NCT00250796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide, alpha interferon
Description: If the patient SSR status is negative, patients will not be given subcutaneous injections of octreotide (Sandostatin LAR) but will receive the thalidomide and alfa interferon only.
Study NCT00250796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide, interferon, Octreotide
Description: If SSR status is positive or unknown, patients will receive oral doses of thalidomide starting at 200mg a day and increasing to 800mg at increments of 200 per week depending on tolerance. They will also receive injections three times a week of alpha interferon and monthly injections of octreotide (Sandostatin LAR) 30 mg into their buttocks muscle..
Study NCT01434186 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching with Saxagliptin
Description: Tablet, Oral, 0.0 mg, Daily, Day 1 through week 52
Study NCT01434186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin IR
Description: Tablet, Oral, 1000 mg -2000 mg, Daily , Day 1 through week 52
Study NCT01434186 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin IR
Description: Tablet, Oral, 1000 mg -2000 mg, Daily , Day 1 through week 52
Study NCT01434186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: Tablet, Oral, 1000 mg -2000 mg, Daily, Day 1 through week 52
Study NCT01434186 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin XR
Description: Tablet, Oral, 1000 mg -2000 mg, Daily, Day 1 through week 52
Study NCT01434186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Saxagliptin Tablet, 2.5 mg, or Saxagliptin Tablet, 5 mg, (based on subject's weight)
Study NCT00663767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo; oral
Description: dose 1, dose 2
Study NCT00663767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo; oral
Description: dose 1
Study NCT00663767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-371797, p38 inhibitor; oral
Description: dose 1: multiple dose levels
Study NCT00663767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-371797, p38 inhibitor; oral
Description: dose 1: multiple dose levels; dose 2
Study NCT00663767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib, COX-2 inhibitor; oral
Description: dose 1
Study NCT00663767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib, COX-2 inhibitor; oral
Description: dose 1
Study NCT00663767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo; oral
Description: dose 2
Study NCT00663767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo; oral
Description: dose 2
Study NCT00663767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-371797, p38 inhibitor; oral
Description: dose 2
Study NCT01330771 — intervention group
Intervention type: DRUG
Intervention: hMG-HP/r-FSH
Study NCT04588714 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience-based, Energy Management to Enhance Wellbeing (RENEW)
Description: The program includes unlimited website access and 10 scheduled phone calls with an assigned peer mentor.
Study NCT02287207 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Study NCT02287207 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Study NCT03668561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Caligaloc
Description: 15 days of wearing of the Caligaloc orthosis
Study NCT02551432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab, paclitaxel
Description: pembrolizumab, paclitaxel
Study NCT04339322 — intervention group
Intervention type: OTHER
Intervention: Follow up
Description: Follow up to assess the outcome until complications, improvement, death or being transferred to another quarantine hospital.
Study NCT02343419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Methacholine Challenge Test
Description: Forced oscillation technique test, plethysmography, interrupter technique test and spirometry will be performed in a row before any intervention and after inhalation of aerosols - normal saline, followed by increasing concentrations of methacholine: 0.03 mg/ml; 0.06 mg/ml; 0.125 mg/ml; 0.25 mg/ml, 0.5 mg/ml, 1 mg/ml, 2 mg/ml, 4 mg/ml, 8 mg/ml, 16 mg/ml.~In case of FEV1 decrease of ≥ 20% of the initial value methacholine challenge test will be ceased and patient will be administered 200 µg of salbutamol in inhalation. Then, pulmonary function tests will be performed after 15 minutes.
Study NCT03449121 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Slow breathing techniques
Description: 8 sessions of instruction in slow breathing exercises over 12 weeks of study
Study NCT03119246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAPIT-HD beta
Description: New assessment protocol for assessment of complex therapies in Huntington's disease for both groups
Study NCT04103775 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: See Cognitive Remediation Arm description.
Study NCT04103775 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: See Active Control Arm description.
Study NCT04213937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Drug: nab-paclitaxel 125mg/m2, i.v. d1, d8, Repeated every 3 weeks for 4-6 cycles.
Study NCT04213937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Drug: Topotecan 1.25mg/m2/d, i.v, 1hour, d1-d5, Repeated every 3 weeks for 4-6 cycles.
Study NCT03613844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for DHA
Study NCT04718298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProFlor laparoscopic technique
Description: Inguinal hernia repair laparoscopic
Study NCT00702039 — intervention group
Intervention type: OTHER
Intervention: No Music
Description: No music will be played in patients in arm 2 of the study.
Study NCT00702039 — intervention group
Intervention type: OTHER
Intervention: Music Therapy
Description: Classical music being played during intravitreal injection.
Study NCT01968759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer
Study NCT01968759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer
Study NCT04580212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Poultry hygiene intervention
Description: The intervention will consist of a series of participatory training exercises designed to accomplish three main goals: (1) increase awareness of health risks and lost livelihood benefits of current poultry management practices, (2) build practical skills for poultry management, and (3) build supportive community norms by facilitating savings group discussions on poultry management. The intervention will be delivered through three activities: (1) triggering exercise designed to raise awareness of both the health risks of the current practices and the economic potential of a more active poultry management approach, and ultimately to motivate participants for behavior change, (2) poultry management training activity based on local needs and norms, and (3) periodic follow-on coaching to reinforce messages from the initial training and emphasize action planning, monitoring of plan execution, and troubleshooting.
Study NCT04219488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radial nerve mobilization
Study NCT01968759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril and Irbesartan
Study NCT01968759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril and Irbesartan
Study NCT01881347 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Resveratrol 100 mg daily for 2 weeks followed by resveratrol 300 mg daily for 2 weeks.
Study NCT04219488 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised home program
Study NCT04219488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised home program
Study NCT03384628 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: First pair Senofilcon A contact lens
Description: Fit assessment of the first pair contact lenses.
Study NCT03384628 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Second pair Senofilcon A contact lens
Description: Fit assessment of the second pair of contact lenses.
Study NCT03384628 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Third pair Senofilcon A contact lens
Description: Fit assessment of the third pair of contact lenses.
Study NCT00265967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Description: Irbesartan 150-300 mg/d for 8 weeks
Study NCT01798017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone and misoprostol
Description: Women will receive 200mg mifepristone followed in 24-48h by 800mcg bucccal misoprsotol
Study NCT04137562 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADSTEM Inj.
Description: Two 5mL of the following study drug is pre-mixed with 320mL of 0.9% normal saline is injected intravenously twice for the duration of the study. Treatment group: ADSTEM Inj. 0.5x10\^8 cells/5mL
Study NCT01881347 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo 100 mg daily for 2 weeks followed by placebo 300 mg daily for 2 weeks.
Study NCT04137562 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 330mL of 0.9% normal saline is injected intravenously twice for the duration of the study.
Study NCT02823080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetrorelix
Description: study group received 3-day Cetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites control (24 patients) did not receive Cetrorelix Acetate. Grading were re-evaluated on Day-3, 6 and 8.
Study NCT00943085 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-focused therapy
Description: 12 therapy sessions involving the at-risk child or adolescent, parents, and available siblings. Therapy will include psychoeducation about mood disorders, communication enhancement training, and problem-solving skills training. Ongoing medication management from a study psychiatrist will be available.
Study NCT00943085 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief educational treatment
Description: Thorough diagnostic assessment by a study evaluator, separate evaluation by a child psychiatrist, feedback session with parents and child, and provision of reading materials pertinent to managing childhood mood disorders. Ongoing medication management and crisis-oriented family sessions will be available as needed.